A Almirall SA
A
Ouvert
SecteurSoins de santé
11.2 0.18
Résumé
Variation du prix de l'action
24h
Min
11.1
Max
11.3
Revenu | -4.3M 15M |
|---|---|
Ventes | -257M 291M |
P/E Moyenne du Secteur | 59.263 50.958 |
BPA | 0.071 |
Rendement du dividende | 1.7 |
Marge bénéficiaire | 5.258 |
Employés | 2,108 |
EBITDA | 135M 237M |
Rendement du dividende Moyenne du Secteur | 1.70% 2.41% |
|---|---|
Prochains Résultats | 24 juil. 2026 |
Capitalisation Boursière | -74M 2.5B |
|---|---|
Ouverture précédente | 11.02 |
Clôture précédente | 11.2 |
Sentiment de l'Actualité
By Acuity
58%
42%
282 / 342 Classement par Healthcare
Almirall SA Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
